
First Patient Enrolled in Phase 3 Trial of Abelacimab for High-Risk Atrial Fibrillation Patients
Anthos Therapeutics has enrolled the first patient in a Phase 3 study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation deemed unsuitable for current ant ...